Page 135 - MEMORIA ANUAL 2020

MEMORIA ANUAL 2020
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
seca JE, Tormo M, Solano C, Clavero E, Romero A, Li Y, Lass-Flörl C, Einsele H, Vázquez L, Loeffler J, Hemminki K, Carvalho A, Netea MG, Gsur A, Dumontet C, Canzian F, Försti A, Jurado M, Sainz J.
• Cancer Testis Antigens in Myelodysplastic Syndromes Revisited: a Targeted RNA-seq Approach.
Oncoimmunology. 2020 Oct 1;9(1):1824642. doi: 10.1080/2162402X.2020.1824642. PMID: 33101773.
Hurtado López AM, Chen-Liang TH, Zurdo M, Carrillo-Tornel S, Panadero J, Salido EJ, Beltrán V, Muiña B, Amigo M, Navarro-Villamor N, Cifuentes R, Calabria I, Antón AI, Teruel R, Muro M, Vicente V, Jerez A.
• Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7.
Leukemia. 2020 Sep;34(9):2441-50. doi: 10.1038/s41375-020-0728-x. PMID: 32066866.
Crisà E, Kulasekararaj AG, Adema V, Such E, Schanz J, Haase D, Shirneshan K, Best S, Mian SA, Kizilors A, Cervera J, Lea N, Ferrero D, Germing U, Hildebrandt B, Martínez ABV, Santini V, Sanz GF, Solé F, Mufti GJ.
• Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Leukemia. 2020 Jun 29. doi: 10.1038/s41375-020-0917-7. Epub ahead of print. PMID: 32595214.
Kuendgen A, Nomdedeu M, Tuechler H, García-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiartzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martínez-de-Sola M, Stauder R, Merchán B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G.
• Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Nat Med. 2020;26(10):1549-56. doi: 10.1038/s41591-020-1008-z. PMID: 32747829. Publicación compartida con el GCECGH.
Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martínez JS, Yoshizato T, Shio- zawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou
GRUPO ESPAÑOL DE SÍNDROMES MIELODISPLÁSICOS (GESMD)
135